My laboratory focuses on development of novel drugs for treatment of myeloma. We evaluate the in vitro activity of novel drugs, which are likely to have activity in the setting of myeloma, based on their mechanisms of action. Promising drugs are brought into the clinic through early stage clinical trials (Phase I/II studies). Additionally we evaluate novel combinations of different drugs to identify synergistic combination which can result in better treatment responses and eventually better patient outcome. The work on drug development is complemented by an active program studying the disease biology. The focus is on the study of bone marrow microenvironment in multiple myeloma and how it influences the tumor cells, especially the increased bone marrow microvessels seen in myeloma. A better understanding of the disease biology allows identification of valid therapeutic targets and in turn development of novel drugs.